Ephrin Receptor
Ephrin receptors (Ephs) are a group of receptors that are activated in response to binding ephrin. Ephs form the largest known subfamily of receptor tyrosine kinases (RTKs). Both Ephs and their corresponding ephrin ligands are membrane-bound proteins that require direct cell-cell interactions for Eph receptor activation. Eph/ephrin signaling has been implicated in the regulation of a host of processes critical to embryonic development including axon guidance, formation of tissue boundaries, cell migration, and segmentation. Additionally, Eph/epherin signaling has recently been identified to play a critical role in the maintenance of several processes during adulthood including long-term potentiation, angiogenesis, and stem cell differentiation and cancer. The ability of Ephs and ephrins to mediate a variety of cell-cell interactions places the Eph/ephrin system in an ideal position to regulate a variety of different biological processes during embryonic development.
Targets for Ephrin Receptor
Products for Ephrin Receptor
- Cat.No. Nombre del producto Información
-
GC35053
123C4
123C4 es un agonista potente, selectivo y competitivo del receptor tirosina quinasa EPHA4, con un valor Ki de 0,65 μM.
-
GC11134
ALW-II-41-27
Eph receptor tyrosine kinase inhibitor;
Un inhibidor de múltiples quinasas.
-
GC68647
ALW-II-49-7
ALW-II-49-7 es un inhibidor selectivo de EphB2 con una EC50 intracelular de 40 nM.
-
GC25367
Ehp-inhibitor-1
Ehp inhibitor 2
Ehp-inhibitor-1 (Ehp inhibitor 2) is an Eph family tyrosine kinase inhibitor that targets Eph receptors. -
GC69258
Ifabotuzumab
KB004
Ifabotuzumab (KB004) is an IgG1κ antibody that targets EphA3 (KD=610 pM). Ifabotuzumab can induce apoptosis in tumor cells and activate antibody-dependent cell-mediated cytotoxicity (ADCC), destroying the tumor vascular system. Ifabotuzumab can reduce CCR10+ cells in idiopathic pulmonary fibrosis (IPF) patients, improving lung fibrosis.
-
GC18168
JI-101
CGI1842
JI-101 es un inhibidor multicinasa disponible por vÍa oral de VEGFR2, PDGFRβ y EphB4 con una potente actividad anticancerÍgena. -
GC50137
KYL
KYL, un péptido antagonista, se dirige selectivamente al receptor EphA4.
-
GC14332
NVP-BHG712
NVP-BHG712 es un inhibidor de la autofosforilaciÓn de la cinasa EphB4 activo por vÍa oral, con valores IC50 de 3,3 nM y 3,0 nM para EphA2 y EphB4, respectivamente.
-
GC36782
NVP-BHG712 isomer
El isÓmero NVP-BHG712, un regioisÓmero de NVP-BHG712, muestra una uniÓn no enlazada conservada a EPHA2 y EPHB4.
-
GC74367
Targefrin
Targefrin es un potente agente epha2, actúa como un antagonista.
-
GC31752
Tesevatinib (XL-647)
EXEL-7647, Tesevatinib
Tesevatinib (XL-647) (XL-647; EXEL-7647; KD-019) es un inhibidor de la tirosina cinasa multidiana disponible por vÍa oral; inhibe la cinasa EGFR, ErbB2, KDR, Flt4 y EphB4 con IC50 de 0,3, 16, 1,5, 8,7 y 1,4 nM. -
GC64856
UniPR129
UniPR129 es un potente antagonista de Eph/ephrin. UniPR129 tiene el potencial para la investigaciÓn de la enfermedad del cÁncer.
-
GC70097
Urolithin D
Urolithin D es un antagonista competitivo y reversible del receptor EphA. Urolithin D muestra selectividad intraclase.